lithium-tauopathy

Low-Dose Lithium for Tauopathy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">lithium-tauopathy</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Best-supported signal</td>
<td>[Tau](/proteins/tau)-phosphorylation biology and mixed dementia-risk observational signal</td>
</tr>
<tr>
<td class="label">Direct PSP/CBS RCT evidence</td>
<td>Absent for lithium-specific disease modification</td>
</tr>
<tr>
<td class="label">Evidence confidence for CBS/PSP progression slowing</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Potential use case</td>
<td>Carefully selected patients in specialist care with formal monitoring</td>
</tr>
<tr>
<td class="label">Key practical limitation</td>
<td>Safety margin (renal, thyroid, neurologic toxicity) and drug interaction complexity</td>
</tr>
<tr>
<td class="label">Risk Tier</td>
<td>Typical Features</td>
</tr>
<tr>
<td class="label">Lower risk</td>
<td>Stable eGFR, reliable caregiver support, low interaction burden, no recurrent dehydration</td>
</tr>
<tr>
<td class="label">Intermediate risk</td>
<td>Mild CKD, moderate polypharmacy, occasional hydration instability, early cognitive fluctuation</td>
</tr>
<tr>
<td class="label">High risk</td>
<td>Progressive CKD, frequent acute illness/delirium, high-risk interaction profile, unreliable medication supervision</td>
</tr>
<tr>
<td class="label">Medication Context</td>
<t

Low-Dose Lithium for Tauopathy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">lithium-tauopathy</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Best-supported signal</td>
<td>[Tau](/proteins/tau)-phosphorylation biology and mixed dementia-risk observational signal</td>
</tr>
<tr>
<td class="label">Direct PSP/CBS RCT evidence</td>
<td>Absent for lithium-specific disease modification</td>
</tr>
<tr>
<td class="label">Evidence confidence for CBS/PSP progression slowing</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Potential use case</td>
<td>Carefully selected patients in specialist care with formal monitoring</td>
</tr>
<tr>
<td class="label">Key practical limitation</td>
<td>Safety margin (renal, thyroid, neurologic toxicity) and drug interaction complexity</td>
</tr>
<tr>
<td class="label">Risk Tier</td>
<td>Typical Features</td>
</tr>
<tr>
<td class="label">Lower risk</td>
<td>Stable eGFR, reliable caregiver support, low interaction burden, no recurrent dehydration</td>
</tr>
<tr>
<td class="label">Intermediate risk</td>
<td>Mild CKD, moderate polypharmacy, occasional hydration instability, early cognitive fluctuation</td>
</tr>
<tr>
<td class="label">High risk</td>
<td>Progressive CKD, frequent acute illness/delirium, high-risk interaction profile, unreliable medication supervision</td>
</tr>
<tr>
<td class="label">Medication Context</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">Diuretics (esp. thiazides)</td>
<td>Increased lithium concentration</td>
</tr>
<tr>
<td class="label">ACE inhibitors / ARBs</td>
<td>Reduced lithium clearance</td>
</tr>
<tr>
<td class="label">NSAIDs (chronic use)</td>
<td>Concentration increase</td>
</tr>
<tr>
<td class="label">Dehydration/illness states</td>
<td>Toxic accumulation</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Required Checks</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Serum creatinine/eGFR, TSH (plus free T4 where needed), electrolytes, calcium, weight, BP, medication reconciliation</td>
</tr>
<tr>
<td class="label">5-7 days after dose change</td>
<td>Trough serum lithium + renal/electrolytes if clinically indicated</td>
</tr>
<tr>
<td class="label">Every 3 months (initial year)</td>
<td>Serum lithium, renal function, adverse-effect screen</td>
</tr>
<tr>
<td class="label">Every 6-12 months (stable phase)</td>
<td>Lithium level, eGFR/creatinine, thyroid panel, medication-interaction review</td>
</tr>
<tr>
<td class="label">Any acute illness/fall/cognitive change</td>
<td>Urgent lithium level + renal labs</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>9</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>7</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>5</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>5</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Total</td>
<td>55/80</td>
</tr>
</table>

Overview

Low-dose lithium is a mechanistically plausible but still evidence-limited strategy for tau-driven neurodegeneration, including [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP) and [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS).[@forlenza2011][@nunes2013][@kessing2010][@kessing2008] The core rationale is that lithium engages several disease-relevant nodes at once: suppression of glycogen synthase kinase-3 beta (GSK3beta), reduction of pathological tau phosphorylation, modulation of inositol signaling, [autophagy](/entities/autophagy) enhancement through inositol monophosphatase inhibition, and neurotrophic signaling support.[@hampel2019][@noble2005][@hong1997][@perez2003][@forlenza2014][@ferrer2002]

In contrast to highly target-specific anti-tau biologics, lithium is a pleiotropic small molecule with a narrow therapeutic index and substantial monitoring burden. For patients and clinicians, that means the scientific question is not simply "does lithium have neurobiologic effects?" (it does), but whether those effects can be translated into clinically meaningful slowing of functional decline in tauopathies with acceptable safety.[@nunes2013][@sarkar2005][@sarkar2008]

The current evidence base is strongest in biomarker/cognition-adjacent settings (mild cognitive impairment and Alzheimer's disease cohorts) and much weaker for direct PSP/CBS outcomes.[@forlenza2011][@nunes2013][@macdonald2008] Accordingly, lithium should be framed as an investigational or individualized adjunct in CBS/PSP, not an established disease-modifying standard.

Clinical Snapshot

Mechanistic Rationale

GSK3beta Inhibition and Tau Phosphorylation

Lithium was one of the earliest clinically used compounds shown to inhibit [GSK3](/entities/gsk3-beta) signaling, a central tau kinase axis in several tauopathies.[@noble2005][@hong1997] Experimental studies demonstrated reduced tau phosphorylation after lithium exposure and attenuation of aggregation phenotypes in tau-transgenic models.[@noble2005][@hong1997][@perez2003][@forlenza2014] Neuropathology studies also place GSK3 activity in PSP/CBD-relevant tau lesions, supporting biological plausibility of this target in 4R tau disease.[@ferrer2002]

Mechanistically, lithium appears to reduce phosphorylation pressure at multiple tau epitopes via direct and indirect GSK3 modulation, which may shift tau away from aggregation-prone conformations.[@noble2005][@hong1997][@ferrer2002] This does not necessarily stop templated tau spread, but it can reduce one upstream driver of pathological tau state transitions.

Inositol Signaling, IMPase, and Autophagy

A second non-redundant mechanism is inhibition of inositol monophosphatase (IMPase), reducing free inositol signaling tone and enhancing autophagic flux in experimental systems.[@sarkar2005][@sarkar2008][@berridge1982] Because impaired proteostasis is a recognized feature across neurodegenerative diseases, this pathway gives lithium a broader "cellular housekeeping" rationale beyond tau kinase effects.[@hampel2019][@sarkar2005][@sarkar2008]

In practice, this mechanism is most compelling as part of combination strategy logic (for example, combining anti-aggregation approaches with interventions that improve aggregate clearance).[@sarkar2008]

Neurotrophic and Anti-apoptotic Programs

Lithium exposure has been associated with pro-survival signaling and neurotrophic pathway modulation, including BDNF-linked biology in preclinical and translational literature.[@hampel2019][@won2017][@dwivedi2015] These signals may increase stress resilience in vulnerable [neurons](/entities/neurons), but effect translation to human tauopathy progression remains uncertain.

Mechanism Diagram

Human Evidence: What Is Actually Known

Randomized Data in MCI / AD-Adjacent Cohorts

The most cited long-duration randomized study in amnestic mild cognitive impairment reported disease-modifying-style signals with long-term lithium exposure and biomarker-relevant effects.[@forlenza2011] A later microdose study in Alzheimer's disease reported stabilization trends in cognitive outcomes.[@nunes2013] Shorter-duration AD trials have produced mixed findings, with some studies underpowered for progression endpoints.[@macdonald2008]

Key interpretation points:

• These studies support biologic activity and a possible signal, not definitive proof of robust clinical disease modification across dementia syndromes.
• Dosing strategies differ considerably across trials (standard low therapeutic range vs microdose approaches), limiting direct comparability.[@forlenza2011][@nunes2013][@macdonald2008]
• Outcome measures vary from biomarker changes to cognitive composites, and most were not designed around PSP/CBS phenotypes.

Observational Data and Dementia Risk

Registry and cohort analyses in bipolar populations have suggested lower dementia incidence among lithium-exposed individuals compared with non-exposed groups.[@kessing2010][@kessing2008] However, observational work remains vulnerable to confounding by indication, health-system contact intensity, differential mortality, and adherence patterns. These datasets are useful for hypothesis support but not sufficient to claim causality in PSP/CBS.

What This Means for PSP/CBS

Direct lithium RCTs in PSP or CBS are lacking. Extrapolation therefore relies on:

Given this evidence geometry, lithium in PSP/CBS should be considered a monitored experimental adjunct rather than routine standard care.

Pharmacokinetics and Exposure-Response in Neurodegeneration Context

Lithium pharmacokinetics are clinically useful because they are simple in principle but fragile in practice. Absorption is generally efficient, distribution approximates total body water, and elimination is primarily renal, with minimal metabolic transformation.[@malhi2013][@mcknight2012][@gitlin2016] In older adults with [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) or [corticobasal syndrome](/diseases/corticobasal-syndrome), the practical challenge is that age-related decline in glomerular filtration, lower muscle mass, and fluctuating hydration can shift exposure quickly even when nominal dose is unchanged.[@rej2014][@mcknight2012][@gitlin2016]

For tauopathy programs, the most actionable concept is exposure-response uncertainty: molecular target engagement may occur at concentrations lower than those traditionally used in acute mood episodes, but high-quality dose-finding data for PSP/CBS are absent.[@nunes2013][@hampel2019][@cabral2024] This creates a narrow operational window where undertreatment may produce no benefit while overtreatment drives toxicity that can mimic neurologic progression. The result is a strong argument for conservative initiation, slower titration than standard psychiatric pathways, and frequent reassessment of both function and tolerability.[@rej2014][@mcknight2012][@nolen2019]

Why "Low Dose" Is Not a Single Regimen

"Low-dose lithium" is often used imprecisely in the literature and clinic conversations. In practice, at least three distinct exposure frameworks exist:

These strategies should not be pooled as if they were equivalent interventions. If future PSP/CBS trials compare "lithium vs placebo" without explicit exposure bands and protocolized monitoring, effect estimates are likely to be noisy and hard to generalize.

Exposure Instability Triggers in CBS/PSP

Common, predictable triggers of unstable lithium exposure in atypical parkinsonism include:

• Reduced oral intake from dysphagia and apraxia-related feeding impairment.[@hglinger2017][@armstrong2013]
• Intercurrent infections with dehydration and electrolyte shifts.
• Medication changes by non-neurology services (thiazides, NSAIDs, ACE inhibitors/ARBs).
• Falls and emergency presentations where lithium history is incompletely reconciled.

Disease-Stage Positioning for CBS/PSP

Not every patient with a tauopathy phenotype has the same therapeutic risk-benefit profile for lithium. A staged approach can improve decision quality and reduce avoidable harm:

Early Stage (Ambulatory, Preserved Caregiver Bandwidth)

In earlier disease with preserved renal reserve and strong follow-up reliability, lithium can be considered as a time-limited, monitored experiment when goals are explicit (for example: slowing mobility decline or preserving activities of daily living over a 6-12 month window). Benefit expectations should remain modest, and continuation should depend on objective trajectory rather than subjective optimism alone.[@jabbari2021][@boxer2014]

Mid Stage (Rising Falls, Polypharmacy, Emerging Frailty)

Mid-stage patients often have the highest uncertainty zone. Potential biologic benefit still exists, but toxicity vulnerability increases. Here, lithium decisions should be integrated with fall-prevention plans, caregiver medication administration checks, hydration routines, and proactive interaction management across all prescribers.[@rej2014][@gitlin2016][@ott2016]

Advanced Stage (High Frailty, Recurrent Delirium, Renal Instability)

In advanced disease, exposure volatility and adverse event risk often dominate expected benefit. In many cases, de-prescribing or non-initiation is the safer evidence-aligned choice unless there is a compelling prior response and unusually stable monitoring infrastructure.

Safety Stratification Framework for Older Tauopathy Patients

A binary "eligible vs ineligible" framing is usually too crude. A practical triage model is to classify candidates as lower-risk, intermediate-risk, or high-risk before initiation:

This framework aligns with published geriatric lithium safety principles and helps prevent indiscriminate use in populations where toxicity is likely to outweigh uncertain efficacy.[@rej2014][@mcknight2012][@gitlin2016]

Neurotoxicity Mimics of Disease Progression

An under-recognized challenge in PSP/CBS clinics is symptom misattribution. Lithium-related gait instability, tremor, bradyphrenia, and confusion can be mistaken for accelerated tauopathy progression, especially during acute illness or medication changes.[@mcknight2012][@ott2016] Any sudden step-down in function should therefore trigger a medication safety workup in parallel with neurologic reassessment rather than assuming inevitable disease acceleration.

Comparative Positioning Against Other Tauopathy Strategies

Lithium should be interpreted as one component in a layered care model, not as a stand-alone disease-modifying solution.

Versus Targeted Anti-tau Programs

Targeted anti-tau biologics are mechanistically specific but currently limited by mixed clinical efficacy, trial-access constraints, infusion burden, and cost. Lithium is less specific but broadly available and orally administered. For many health systems, this makes lithium a pragmatic adjunct candidate while high-certainty anti-tau options remain limited.[@boxer2014][@stamelou2008]

Versus Non-pharmacologic Neuroprotection

Compared with exercise, swallowing therapy, multidisciplinary rehabilitation, and caregiver-mediated risk reduction, lithium carries higher direct toxicity risk but potentially stronger molecular target engagement in tau-kinase and proteostasis pathways.[@jabbari2021][@livingston2020] A reasonable framework is "rehabilitation-first, lithium-selective": standard supportive interventions for everyone, lithium only in candidates who can safely sustain monitoring.

Versus Other Repurposed Metabolic/Mitochondrial Agents

Agents such as coenzyme Q10, creatine, and other metabolic adjuncts often have safer tolerability but weaker or inconsistent efficacy signals in atypical parkinsonism trials.[@stamelou2008] Lithium's comparative advantage is mechanistic depth around [GSK3B](/genes/gsk3b)-linked tau regulation and autophagy. Its comparative disadvantage is safety complexity and monitoring burden.

Translational Biomarkers and Trial-Ready Endpoints

To improve inferential quality, future PSP/CBS lithium studies need tighter linkage between exposure, target engagement, and clinical trajectory. Candidate endpoint domains include:

Inference strength will improve if trials predefine exposure bands, enforce interaction-management algorithms, and report adverse-event adjudication by renal and endocrine baseline status.[@rej2014][@mcknight2012][@iesaka2023]

Trial Blueprint for CBS/PSP Lithium Studies

The current evidence gap is not simply "too few studies"; it is a design-quality gap. A practical next-generation protocol could include:

• Population: probable PSP-Richardson syndrome and biomarker-supported corticobasal syndrome strata with separate randomization blocks.
• Design: multi-center, randomized, placebo-controlled, adaptive dose-ranging with prespecified exposure strata.
• Duration: at least 12-18 months to avoid false-negative conclusions from short follow-up in slowly progressive subsets.
• Primary endpoint: change in PSP Rating Scale slope or equivalent composite selected per phenotype.
• Secondary endpoints: falls, caregiver burden, swallowing events, hospitalization days, and biomarker trajectories.
• Safety core: centralized algorithm for sick-day rules, drug-interaction alerts, and immediate toxicity adjudication.

Practical Implementation Workflow (Specialist Clinics)

For teams choosing individualized off-label use, a protocolized workflow reduces preventable harm:

Step 1: Pre-initiation Conference

Neurology, prescribing clinician, patient, and caregiver align on realistic goals, non-goals, monitoring obligations, and explicit discontinuation triggers. Written plans should include dehydration management and emergency contact pathways.

Step 2: Structured Baseline

Capture objective baseline metrics before first dose:

• Functional scores (mobility, transfers, ADLs).
• Fall frequency over prior 4-8 weeks.
• Cognition/behavior snapshot.
• Renal, thyroid, electrolytes, and medication interaction map.

Step 3: Conservative Start and Verification

Use low starting dose, perform early trough check after dose changes, and require active confirmation that concurrent prescribers know lithium is on the medication list.[@iesaka2023][@collins2010]

Step 4: Benefit-Harm Review Gate

At predefined intervals (for example 3 and 6 months), classify response as:

• probable benefit,
• uncertain/no benefit,
• or net harm.

Step 5: Exit Pathway

When stopping, document reason (inefficacy, toxicity, interaction burden, renal trajectory) so decisions can inform future N-of-1 learning and registry analytics.

CBS/PSP-Specific Relevance

PSP and corticobasal syndromes are often 4R tauopathies characterized by severe network degeneration, early axial/motor disability, falls, and progressive loss of independence.[@hglinger2017][@armstrong2013][@rej2014][@jabbari2021][@boxer2014] A compound that modestly improves tau phosphorylation state may still underperform clinically if it does not sufficiently affect tau seeding, spread, synaptic collapse, and systems-level degeneration.

Practical implications for specialist clinics:

• Expect modest effect size at best in unselected patients.
• Prioritize objective longitudinal tracking (PSP Rating Scale variants, timed mobility metrics, fall frequency, caregiver burden indices).
• Frame use as time-limited therapeutic trial with pre-specified continuation/stop rules.

Formulation and Dose Strategy

Lithium Carbonate (Current Clinical Standard)

Most evidence and safety infrastructure are based on lithium carbonate, with dosing titrated to serum concentrations by indication, age, and comorbidity profile.[@malhi2013][@mcknight2012] In neurodegeneration-focused exploratory use, clinicians generally prefer conservative targets, slower titration, and lower peak exposure than typical acute psychiatry protocols.

Microdose Frameworks

Microdose strategies are increasingly discussed because of cognitive-stabilization signals with lower exposure and potentially fewer adverse effects, but evidence remains small-scale and not yet standardized for PSP/CBS.[@nunes2013][@cabral2024]

Lithium Orotate vs Carbonate

Lithium orotate is marketed as a supplement in some regions, but comparative human PK/PD, efficacy, and safety evidence remains sparse relative to lithium carbonate.[@cabral2024][@chuang2007] Key concerns include uncertain bioequivalence, weaker regulatory oversight, and reduced consistency of laboratory-monitoring frameworks. For medically supervised tauopathy care, carbonate remains the evidence-anchored form when lithium is used.

Safety, Contraindications, and Adverse Effects

Lithium has a narrow therapeutic window. Common chronic risks include tremor, gastrointestinal symptoms, cognitive slowing, polyuria/polydipsia, thyroid dysfunction, and renal impairment with cumulative exposure.[@mcknight2012][@gitlin2016][@iesaka2023] Acute toxicity risk rises with dehydration, renal decline, interacting medications, and dosing errors.[@ott2016]

High-Priority Interaction Risks

Endocrine and Renal Surveillance

Thyroid and kidney surveillance are mandatory in chronic use, with baseline and interval reassessment throughout therapy.[@rej2014][@malhi2013][@mcknight2012][@nolen2019] Older adults with neurodegeneration are particularly vulnerable because frailty, impaired thirst response, and multimorbidity can rapidly destabilize lithium kinetics.

Monitoring Protocol (Operational)

The table below reflects a pragmatic specialist protocol derived from monitoring consensus literature and long-term lithium safety practice.[@rej2014][@malhi2013][@mcknight2012][@nolen2019][@collins2010]

Suggested Stop Rules in Tauopathy Programs

• Progressive eGFR decline attributable to lithium.
• Recurrent neurotoxicity (ataxia, confusion, coarse tremor) despite dose reduction.
• Persistent hypothyroidism or hyperparathyroid trends not manageable within patient goals.
• No measurable clinical/functional benefit after a predefined trial period.

Benefit-Risk Positioning for CBS/PSP

A defensible clinical position is:

Therefore, best candidates are typically those with:

• clear specialist follow-up access,
• reliable caregiver-assisted medication management,
• and capacity for structured monitoring.

Comparative Practicality Versus Other Neuroprotective Adjuncts

Compared with low-risk lifestyle strategies and some nutraceutical-style interventions, lithium is more pharmacologically potent but substantially more monitoring-intensive.[@jabbari2021][@boxer2014][@livingston2020] Compared with highly targeted anti-tau biologics, lithium is less specific but more accessible and lower-cost. In real-world care, it may function as a bridge adjunct while definitive disease-modifying evidence for PSP/CBS remains limited.

Research Priorities

Evidence Quality Rubric (CBS/PSP-Focused)

Bottom Line

Low-dose lithium is one of the more biologically coherent repurposing candidates for tauopathy, supported by decades of mechanistic work and selective human signals in dementia-adjacent populations.[@forlenza2011][@nunes2013][@kessing2010][@hampel2019] The central limitation is evidence transfer: robust direct progression data in PSP/CBS are still missing. Until that gap closes, lithium should be treated as a monitored, individualized adjunct strategy in specialist care rather than default disease-modifying therapy.

CBS/PSP Cross-Link Map

This page is part of a larger CBS/PSP care graph spanning mechanistic, biomarker, and implementation pages:

• Core disease context: [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), [Corticobasal Syndrome](/diseases/corticobasal-syndrome), [Corticobasal Degeneration](/diseases/corticobasal-degeneration), [PSP Genetic Variants](/diseases/psp-genetic-variants), [Primary Age-Related Tauopathy](/diseases/primary-age-related-tauopathy)
• Mechanism context: [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms), [Cortisol-Tau Pathway](/mechanisms/cortisol-tau-pathway), [Gut-Brain Axis in Tauopathy](/mechanisms/gut-brain-axis-tauopathy)
• Biomarker context: [Biomarkers for Progressive Supranuclear Palsy](/biomarkers/progressive-supranuclear-psp-biomarkers), [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp), [MRI Atrophy Patterns in CBS/PSP](/biomarkers/mri-atrophy-cbs-psp), [DTI White Matter Changes in CBS/PSP](/biomarkers/dti-white-matter-cbs-psp)
• Care pathway context: [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan), [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide), [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide), [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
• Adjacent intervention pages: [Exercise and Physical Activity for CBS/PSP](/therapeutics/exercise-cbs-psp), [Cognitive Reserve Strategies for CBS and PSP](/therapeutics/cognitive-reserve-cbs-psp), [Melatonin for Tauopathy](/therapeutics/melatonin-tauopathy), [Rapamycin for Tauopathy](/therapeutics/rapamycin-tauopathy), [Spermidine Neurodegeneration Strategy](/therapeutics/spermidine-neurodegeneration), [Senolytics for Neurodegeneration](/therapeutics/senolytics-neurodegeneration)
• Combination and systems-support pages: [Mitochondrial Support Strategies for CBS/PSP](/therapeutics/mitochondrial-neuroprotection), [Autophagy Enhancement for Tauopathy](/therapeutics/autophagy-enhancement-tauopathy), [Coenzyme Q10 for Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration), [NAD+ Precursors for Neurodegeneration](/therapeutics/nad-precursors-neurodegeneration), [Alpha-Lipoic Acid for Neurodegeneration](/therapeutics/alpha-lipoic-acid-neurodegeneration), [Omega-3 Fatty Acids for Neurodegeneration](/therapeutics/omega-3-fatty-acids-neurodegeneration), [Curcumin for Neurodegeneration](/therapeutics/curcumin-neurodegeneration), [Vitamin D Therapy for Neurodegeneration](/therapeutics/vitamin-d-therapy-neurodegeneration), [Ambroxol for Neurodegeneration](/therapeutics/ambroxol-neurodegeneration), [Photobiomodulation for Neurodegeneration](/therapeutics/photobiomodulation-neurodegeneration), [TUDCA and UDCA for Neurodegeneration](/therapeutics/tudca-udca-neurodegeneration), [Resveratrol for Neurodegeneration](/therapeutics/resveratrol-neurodegeneration), [Urolithin A for Neurodegeneration](/therapeutics/urolithin-a-neurodegeneration), [Mediterranean and MIND Diet for Neurodegeneration](/therapeutics/mediterranean-mind-diet-neurodegeneration)

See Also

• [GSK-3β and Tau Phosphorylation](/mechanisms/gsk3-beta-tau-phosphorylation)
• [Tau Protein](/proteins/tau)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Clinical trial registry
• [CurePSP](https://www.curepsp.org/) — PSP and CBS patient advocacy and research

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF

Related Analyses:

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;